Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €75.11 EUR
Change Today -4.49 / -5.64%
Volume 0.0
WMD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 4:46 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (WMD) Snapshot

Open
€75.45
Previous Close
€79.60
Day High
€78.04
Day Low
€75.11
52 Week High
04/14/15 - €129.23
52 Week Low
10/16/14 - €67.22
Market Cap
6.1B
Average Volume 10 Days
45.2
EPS TTM
--
Shares Outstanding
81.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (WMD)

medivation inc (WMD) Related Businessweek News

View More BusinessWeek News

medivation inc (WMD) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company’s prostate cancer clinical trials include STRIVE, which is in Phase II clinical trial; PROSPER and EMBARK for which enrollment is ongoing for the Phase III clinical trial; PLATO, which is in the Phase IV clinical trial; AFFIRM and PREVAIL that have completed enrollment for the Phase III clinical trial; and TERRAIN for which enrollment is completed for the Phase II clinical trial. Its breast cancer clinical trials comprise AR+, TNBC, ER+ or PgR+ and HER2 Normal, and AR+ HER2 Amplified that are in Phase II clinical trials. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. The company is headquartered in San Francisco, California.

485 Employees
Last Reported Date: 02/25/15

medivation inc (WMD) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $787.5K
Chief Financial Officer
Total Annual Compensation: $465.3K
Chief Medical Officer
Total Annual Compensation: $500.0K
Chief Commercial Officer
Total Annual Compensation: $179.7K
Compensation as of Fiscal Year 2014.

medivation inc (WMD) Key Developments

Medivation, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year 2015

Medivation, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported collaboration revenue of $175,657,000 against $148,090,000 a year ago. Income from operations was $53,655,000 against $54,951,000 a year ago. Income before income tax expense was $40,426,000 against $49,530,000 a year ago. Net income was $25,826,000 against $47,919,000 a year ago. Diluted net income per common share was $0.31 against $0.60 a year ago. Non-GAAP collaboration revenue was $174,811,000 against $81,858,000 a year ago. Non-GAAP net income was $48,688,000 against $4,411,000 a year ago. Non-GAAP diluted net income was $48,688,000 against $4,411,000 a year ago. Non-GAAP diluted net income per share was $0.58 against $0.05 a year ago. For the six months, the company reported collaboration revenue of $304,845,000 against $235,279,000 a year ago. Income from operations was $54,228,000 against $46,486,000 a year ago. Income before income tax expense was $35,528,000 against $35,806,000 a year ago. Net income was $22,708,000 against $34,254,000 a year ago. Diluted net income per common share was $0.28 against $0.43 a year ago. Non-GAAP collaboration revenue was $302,588,000 against $149,814,000 a year ago. Non-GAAP net income was $62,098,000 against $355,000 a year ago. Non-GAAP diluted net income was $63,196,000 against $355,000 a year ago. Non-GAAP diluted net income per share was $0.74 against $0.00 a year ago. The company revised earnings guidance for the full year 2015. For the period, the company expects non-GAAP collaboration revenue of $670 million to $700 million compared to previous guidance of $600 billion to $650 billion. The company's 2015 GAAP and Non-GAAP tax rate is expected to be 36% to 37%, excluding any benefit for the federal R&D credit, which expired at December 31, 2014. Non-GAAP operating expenses of $410 million to $450 million.

Medivation, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Medivation, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 06, 2015

Medivation, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Medivation, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WMD:GR €75.11 EUR -4.49

WMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.44 USD -0.45
Insys Therapeutics Inc $32.42 USD -1.41
Pfizer Ltd/India 2,345 INR -15.05
Sanofi India Ltd 3,875 INR -64.70
Seattle Genetics Inc $40.27 USD -1.98
View Industry Companies
 

Industry Analysis

WMD

Industry Average

Valuation WMD Industry Range
Price/Earnings 29.8x
Price/Sales 9.4x
Price/Book 14.0x
Price/Cash Flow 28.5x
TEV/Sales 8.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.